Last Price$78.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/03/20

Today's Change+1.52(1.97%)
Bid (Size)$75.81 (1)
Ask (Size)$79.49 (1)
Day Low / High$77.24 - 79.49
Volume2.2 M

Eli Lilly, Incyte Say Investigational Study of Eczema Drug Met Primary Endpoint

6:46AM ET 2/12/2020 MT Newswires
Eli Lilly (LLY) and joint venture partner Incyte (INCY) said late Tuesday that the third phase of their investigational study has proven baricitinib to be safe and effective in treating moderate to severe eczema.

The BREEZE-AD5 study compared baricitinib with placebo to test its efficacy and safety at 1-mg and 2-mg doses.

Based on the results, baricitinib met the primary endpoint, with participants achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at week 16. Baricitinib also met key secondary endpoints such as clear or almost clear skin.

Price: 144.25, Change: -1.26, Percent Change: -0.87